Effectiveness of Statins in Reducing the Rate of Severe Sepsis: A Retrospective Evaluation
- 6 January 2007
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (1), 20-26
- https://doi.org/10.1592/phco.27.1.20
Abstract
To determine whether use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) is associated with a reduced rate of severe sepsis, and to further characterize the effect of statins on the frequency of organ dysfunction in patients with severe sepsis. Retrospective cohort study. University-associated teaching hospital. Fifty-three patients admitted with sepsis; 16 were receiving statins and 37 were not receiving statins (controls) before admission. Patients were identified by the International Classification of Diseases, Ninth Revision, Clinical Modification codes. Patient demographics, vital signs, and laboratory values were collected from their electronic medical records. The primary end point was rate of severe sepsis, defined in accordance with guidelines from the American College of Chest Physicians and the Society of Critical Care Medicine. Secondary end points were in-hospital mortality rate and rate of five categories of organ dysfunction (cardiovascular, renal, pulmonary, hematologic, and metabolic). Preadmission statin therapy, compared with no statin therapy, was associated with a 30% lower rate of severe sepsis (56% vs 86%, p<0.02). In-hospital mortality was not significantly different between groups (38% vs 49%, p=0.33); however, the rate of cardiovascular dysfunction, defined as hypotension requiring vasopressor therapy, was significantly lower in the statin group (38% vs 73%, p<0.02). No significant differences in the other organ dysfunction categories were noted between groups. Statins appear to prevent sepsis from becoming severe, most notably through prevention of sepsis-induced hypotension. This potential role for statins in the prevention and treatment of severe sepsis should be further evaluated in a randomized controlled trial.Keywords
This publication has 22 references indexed in Scilit:
- HMG-CoA Reductase Inhibitor Simvastatin Profoundly Improves Survival in a Murine Model of SepsisCirculation, 2004
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003
- Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cellsBiochemical Journal, 2001
- Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cellsLife Sciences, 2000
- Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cellsAtherosclerosis, 1999
- The Dynamics of Disease Progression in Sepsis: Markov Modeling Describing the Natural History and the Likely Impact of Effective Antisepsis AgentsClinical Infectious Diseases, 1998
- Long-term survival after intensive care unit admission with sepsisCritical Care Medicine, 1995
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1992
- Effect of High-Dose Glucocorticoid Therapy on Mortality in Patients with Clinical Signs of Systemic SepsisNew England Journal of Medicine, 1987
- A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 1987